NEW YORK – Renovaro Biosciences said Tuesday that its newly acquired subsidiary GediCube has executed a binding letter of intent (LOI) to acquire 75 percent of Dutch liquid biopsy firm Cyclomics, which has developed a circulating tumor DNA detection technology using Oxford Nanopore sequencing.
Separately on Tuesday, Renovaro said that it had completed the acquisition of GediCube, which will now operate under the name RenovaroCube.
The company did not disclose financial terms of either deal.
According to Renovaro, the Cyclomics method, dubbed CyclomicsSeq, ensures that even a single ctDNA molecule in the blood can be detected at what it called "very high accuracy."
Cyclomics intends to use the technique to develop multiomic tests that can be run using a single vial of blood for cancer early detection, recurrence monitoring, and precision oncology treatment personalization.
The firm has already developed an in vitro diagnostic kit called CyclomicsSeq TP53 for early detection of head and neck tumors or other cancers that harbor TP53 mutations.
RenovaroCube is focused on developing advanced diagnostic and monitoring tests incorporating genomics, epigenomics, transcriptomics, proteomics, fragmentomics, and metabolomics. As a member of the Nvidia Inception Program, the company also intends to integrate medical imaging into its AI engine.
"Together, I believe we will change the field," said RenovaroCube CEO Coenraad van Kalken. "There is enormous power in applying AI to multiple omics data layers that can be detected from a vial of blood from every patient with cancer."